Online citations, reference lists, and bibliographies.
← Back to Search

Trospium Chloride And Oxybutynin Hydrochloride In A German Study Of Adults With Urinary Urge Incontinence: Results Of A 12-week, Multicenter, Randomized, Double-blind, Parallel-group, Flexible-dose Noninferiority Trial.

Michael Zellner, H. Madersbacher, H. Palmtag, M. Stoehrer, R. Boedeker
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVES The aims of this study were to determine whether oral trospium chloride is noninferior to oxy-butynin for urinary urge incontinence and to evaluate its efficacy, tolerability, and health-related quality of life parameters. METHODS In this randomized, double-blind, active-controlled, parallel-group, multicenter, Phase IIIb trial conducted in Germany, male and female outpatients aged >or=18 years with documented urinary frequency (>or=8 micturitions/24 hours) plus urge incontinence (>or=5 episodes/week) were randomized to receive oral treatment with trospium chloride 15 mg TID or oxybutynin hydrochloride 2.5 mg TID for 12 weeks. Daily doses could be adjusted upward after 4 weeks, to 90 mg of trospium (30 mg TID) and 15 mg of oxybutynin (5 mg TID), respectively, if needed. The absolute reduction in weekly episodes of urinary urge incontinence was evaluated as the primary efficacy variable. Secondary variables included the absolute reduction of micturitions per 24 hours, intensity of urgency, and mean voided volume. Qualitative symptom changes were recorded from the patients' entries in their micturition diaries at baseline, at week 4, and at week 12 of treatment. Subjective treatment outcome was assessed by patient ratings on a visual analog scale (VAS), the King's Health Questionnaire (KHQ), and the 36-Item Medical Outcomes Study Short-Form General Health Survey (SF-36); intensity of dry mouth was also recorded on a scale. Adverse events (AEs) were assessed. RESULTS Of the 1658 patients treated, 828 patients (49.9%) received trospium 45 mg/d and 830 patients (50.1%) received oxybutynin 7.5 mg/d. After 4 weeks, daily doses were doubled in 29.2% (242/828) of patients in the trospium chloride group, and in 23.3% (193/830) of patients in the oxybutynin group, until the end of treatment. No clinically relevant differences in demographic characteristics were observed between the treatment groups. Trospium was noninferior to oxybutynin hydrochloride in terms of the reduction in the number of weekly urge incontinence episodes after 4 and 12 weeks of treatment. In the per-protocol population, the median change after 12 weeks was -11.0 in both groups. In the full analysis set, the median change was -10.42 with trospium chloride and -10.00 with oxybutynin (P < 0.001 for the noninferiority hypothesis, for both the per-protocol and the full analysis set calculations). There was also no indication of a difference between groups concerning the observed reductions of daily micturitions and intensity of urgency as well as the increase in micturition volume at the end of 12 weeks. VAS, KHQ, and SF-36 scores were improved to a similar extent in both treatment groups at the end of treatment. Worsening of dry mouth was less common in the trospium group than in the oxybutynin group after 4 and 12 weeks (46.9% vs 63.9% and 51.2% vs 64.4%, respectively; bothtime points, P < 0.001 between groups). Treatment-related AEs were reported by 22.7% (188/828) of the trospium chloride group and 26.5% (220/830) of the oxybutynin group. Dry mouth was the most frequently occurring AE, reported by 4.1% (34/828) of patients in the trospium group and 7.7% (64/830) of the oxybutynin group. CONCLUSIONS Our findings indicate that trospium chloride was noninferior to oxybutynin hydrochloride, both with flexible dosing, over 12 weeks in these patients with urinary urge incontinence. Both drugs were generally well tolerated in the population studied, but fewer patients who received trospium reported worsening of dry mouth than those who received oxybutynin. German Federal Institute for Drugs and Medical Devices Registration Number 4022383.
This paper references
10.1016/j.eururo.2005.08.001
Corrigendum to “The Effects of Antimuscarinic Treatments in Overactive Bladder: A Systematic Review and Meta-Analysis” [Eur Urol 2005;48:5–26]
C. Chapple (2005)
10.1016/S0090-4295(00)01113-4
Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.
P. V. van Kerrebroeck (2001)
10.1016/S1474-4422(03)00622-7
Antimuscarinics for treatment of overactive bladder
K. Andersson (2004)
10.1016/j.urology.2007.12.017
Fesoterodine dose response in subjects with overactive bladder syndrome.
V. Khullar (2008)
10.1111/j.1471-0528.2004.00129.x
How much is enough and who says so?
C. Kelleher (2004)
10.1111/j.1464-410X.2007.07205.x
Muscarinic receptor antagonists for overactive bladder
P. Abrams (2007)
10.1016/J.UROLOGY.2006.05.044
Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures.
P. Abrams (2006)
10.1016/J.UROLOGY.2006.02.046
Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit.
D. Marschall-Kehrel (2006)
10.1007/s00345-003-0321-8
Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability
M. Halaška (2003)
10.1517/13543776.14.7.1041
An appraisal of recently patented compounds for bladder overactivity and urinary incontinence
G. D'Agostino (2004)
10.2165/00044011-200121080-00005
Randomised, Double-Blind, Placebo-Controlled Study on the Efficacy and Tolerance of Trospium Chloride in Patients with Motor Urge Incontinence
B. Ulshöfer (2001)
10.1007/s00228-008-0600-9
Persistence of antimuscarinic drug use
S. Brostrøm (2008)
10.1016/J.UROLOGY.2005.08.017
Multicenter phase III trial studying trospium chloride in patients with overactive bladder.
D. Rudy (2006)
Special issue. Translating functional health and well-being: International Quality of Life Assessment (IQOLA) Project Studies of the SF-36 Health Survey. Issue dedicated to Denis Bucquet.
D. Bucquet (1998)
10.1016/J.UROLOGY.2006.05.043
The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis.
V. Khullar (2006)
10.1023/A:1023422208910
Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder
P. R. Reese (2004)
10.1007/PL00007103
Oxybutynin and the overactive bladder
K. Andersson (2001)
10.1016/S0090-4295(02)01784-3
Definition and epidemiology of overactive bladder.
A. Wein (2002)
10.1002/HEC.4730020305
The RAND 36-Item Health Survey 1.0.
R. Hays (1993)
10.1007/s00120-005-0791-y
Prävalenz der Urininkontinenz in der deutschen Bevölkerung
M. Beutel (2005)
10.1016/S0022-5347(05)68810-6
Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group.
R. Anderson (1999)
10.1080/01621459.1963.10500879
Chi-square tests with one degree of freedom
N. Mantel (1963)
10.1007/s00345-005-0507-3
Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder
N. Zinner (2005)
10.1007/s00391-006-0352-z
[Subjective health of older people in view of the SF-36: Values from a large community-based sample].
T. Gunzelmann (2006)
10.1159/000096338
Propiverine Hydrochloride Immediate and Extended Release: Comparison of Efficacy and Tolerability in Patients with Overactive Bladder
K. Jünemann (2006)
Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies.
S. Hegde (2004)
10.1023/A:1016370925601
Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q
K. Coyne (2004)
10.1002/NAU.20041
ICIQ: A brief and robust measure for evaluating the symptoms and impact of urinary incontinence
K. Avery (2004)
10.1046/j.1464-410x.1999.00397.x
The pharmacological treatment of urinary incontinence
Andersson (1999)
10.1214/AOMS/1177704172
Estimates of Location Based on Rank Tests
J. L. Hodges (1963)
10.4037/CCN1997.17.6.112
Whose quality of life?
A. Bond (1997)
10.1002/NAU.10052
The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence Society
P. Abrams (2002)
10.1111/j.1471-0528.1997.tb11006.x
A new questionnaire to assess the quality of life of urinary incontinent women
C. Kelleher (1997)
10.1111/j.1464-410X.2005.05454.x
A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder
C. Chapple (2005)
10.1016/J.EURURO.2005.04.018
Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow.
C. Chapple (2005)
10.4065/78.6.687
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
A. Diokno (2003)
10.1093/JNCI/22.4.719
Statistical aspects of the analysis of data from retrospective studies of disease.
N. Mantel (1959)
10.3834/UIJ.1944-5784.2009.04.02
Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Noninterventional Trial Showing Use of Flexible Dosing
Andreas Wiedemann (2009)
Antimuscarinic drugs for the treatment of overactive bladder: are they really all the same? - A comparative review of data pertaining to pharmacological and physiological aspects
A. Wiedemann (2007)
Overactive bladder significantly affects quality of life.
P. Abrams (2000)
10.1007/S00120-005-0791-Y
[Prevalence of urinary incontinence in the German population].
M. Beutel (2005)
10.1002/NAU.20092
Psychometric properties and validation of the German‐language King's Health Questionnaire in women with stress urinary incontinence
V. Bjelic-Radisic (2005)
10.1016/S0090-4295(97)00599-2
Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.
R. Appell (1997)
Muscarinic receptor subtypes and smooth muscle function.
R. Eglen (1996)
10.1016/S0090-4295(97)00600-6
Discussion: Tolterodine for treatment of the overactive bladder
P. Norton (1997)
10.1002/14651858.CD003781.PUB2
Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.
G. Nabi (2006)
10.1111/J.1464-410X.1995.TB07264.X
Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia.
H. Madersbacher (1995)
SF-36 physical and mental health summary scales : a user's manual
J. Ware (1994)
10.1097/MOU.0b013e32832ce8a4
Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence
K. Andersson (2009)
10.1136/bmj.326.7394.841
Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review
P. Herbison (2003)
10.1046/j.1464-410x.2000.00575.x
Efficacy of trospium chloride in patients with detrusor instability: a placebo‐controlled, randomized, double‐blind, multicentre clinical trial
L. Cardozo (2000)
10.1016/J.UROLOGY.2006.05.045
Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.
L. Brubaker (2006)
10.1097/01.JU.0000127742.73136.0C
Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial.
N. Zinner (2004)
10.1097/01.JU.0000140729.07840.16
Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.
L. Cardozo (2004)



This paper is referenced by
10.1007/s00129-019-4389-7
Überaktive Blase – aktuelle diagnostische und therapeutische Aspekte
C. Reisenauer (2019)
10.1080/17512433.2020.1779056
The clinical pharmacology of the medical treatment for overactive bladder in adults
Hadi Mostafaei (2020)
Case Study Comparing Bayesian and Frequentist Approaches for Multiple Treatment Comparisons
B. Carlin (2013)
10.4137/CMU.S5068
OAB Update: Focus on Trospium
Alex Gomelsky (2011)
10.1016/j.ejogrb.2013.12.024
Pharmacological approach to overactive bladder and urge urinary incontinence in women: an overview.
L. Cipullo (2014)
10.2147/RRU.S40034
Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life
J. Jayarajan (2013)
10.23970/AHRQEPCCER212
Nonsurgical Treatments for Urinary Incontinence in Women: A Systematic Review Update
E. Balk (2018)
10.1007/978-3-319-67555-8_20
Major or Mild Neurocognitive Disorders with Lewy Bodies
Poh Choo How (2018)
10.1007/s11606-019-05028-0
Adverse Events Associated with Nonsurgical Treatments for Urinary Incontinence in Women: a Systematic Review
Ethan M. Balk (2019)
10.1097/AOG.0000000000000851
Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women: A Systematic Review and Meta-analysis
W. S. Reynolds (2015)
10.7326/M13-2410
Nonsurgical management of urinary incontinence in women: a clinical practice guideline from the American College of Physicians.
A. Qaseem (2014)
10.1186/s12894-018-0394-8
Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective non-interventional study
A. Ivchenko (2018)
10.1007/s00120-013-3153-1
Blasenüberaktivität im Alter
T. Bschleipfer (2013)
10.1097/SPV.0000000000000076
Pharmacological Treatment of Urinary Incontinence
L. Cipullo (2014)
10.3834/UIJ.1944-5784.2011.02.17
Efficacy and Safety of Trospium Chloride Use in Children With Idiopathic and Neurogenic Detrusor Overactivity: An Overview of Available Data
Maria Bürst (2011)
10.7326/0003-4819-156-12-201206190-00436
Benefits and Harms of Pharmacologic Treatment for Urinary Incontinence in Women
T. Shamliyan (2012)
Overactive bladder-pharmacological treatment Participants :
C. Sacomani (2019)
10.1590/1806-9282.63.03.197
Overactive bladder: pharmacological treatment.
J. Truzzi (2017)
10.13188/2332-3442.1000010
Pharmacologic Management of Overactive Bladder and Urge Incontinence: A Review of New and Old Treatment Options
Leslie Matthews (2014)
10.1007/s00404-010-1720-x
Anticholinergic therapy: do the patients take the pills prescribed?
K. Jundt (2010)
10.1186/1471-2490-10-15
Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence
R. Boedeker (2010)
10.1002/14651858.CD005429.pub2
Which anticholinergic drug for overactive bladder symptoms in adults.
P. Madhuvrata (2012)
10.1016/j.eururo.2012.08.060
Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses.
Nora Buser (2012)
Semantic Scholar Logo Some data provided by SemanticScholar